Fennec Pharmaceuticals (FENC) Operating Leases (2023 - 2024)
Fennec Pharmaceuticals (FENC) posted Operating Leases of $2000.0 for Q4 2024, down 71.43% on a QoQ basis from $7000.0 in Q3 2024, and little changed year-over-year from $2000.0 in Q1 2024.
Fennec Pharmaceuticals (FENC) Operating Leases (2023 - 2024) Analysis & Trends
Fennec Pharmaceuticals' Operating Leases history runs 2 years deep, the most recent figure standing at $2000.0 for Q4 2024.
- Quarterly Operating Leases changed 0.0% year-over-year to $2000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2000.0 (changed 0.0% YoY) and the FY2024 annual result came in at $2000.0, changed 0.0% from the prior year.
- Operating Leases was $2000.0 for Q4 2024 at Fennec Pharmaceuticals, down from $7000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $17000.0 in Q1 2024 and bottomed at $2000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Fennec Pharmaceuticals | 346.75 Mn | 309.97 Mn | 12.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 17,000.00 |
| Dec 31, 2023 | 2,000.00 |
| Sep 30, 2023 | 7,000.00 |